Investigation of The Relationship Between Asprosin Levels and Metabolic Parameters Observed in Clinical Follow-Up in Patients with Type 2 Diabetes

Year 2019, , 128 - 133, 01.09.2019

Ahmet Çagdaş Acara Aslı Güler

https://doi.org/10.30621/jbachs.2019.628

Abstract

Objectives: Asprosin is a newly identified adipokine which is involved in glucose and lipid metabolisms as well as inflammation. Type 2 diabetes mellitus T2DM associated with dysfunctions in glucose and lipid metabolisms is known as a metabolic disorder. The aim of this study was to investigate whether asprosin levels were changed in subjects with newly diagnosed T2DM nT2DM comparing to subjects with normal glucose tolerance NGT and to determine if asprosin levels were linked to metabolic parameters. Method: This case control study included 68 subjects with nT2DM and 68 NGT age-, body mass index BMI - and gender-matched subjects. We used ELISA method for measuring the circulating asprosin levels. A 2-h 75-g oral glucose tolerance test was used for diagnosing of T2DM. Metabolic parameters of enrolled subjects were determined.Results: Circulating asprosin levels were elevated in nT2DM subjects when compared to controls. 6.75 ± 1.54 vs. 4.05 ± 1.28 ng/ml, P < 0.001 . Moreover, asprosin levels were found to be higher in nT2DM subjects with metabolic syndrome comparing to those without metabolic syndrome. Correlation analysis revealed that asprosin levels positively correlated with insulin, fasting blood glucose, insulin resistance and triglycerides whereas it displayed negative correlation with HDL cholesterol in only nT2DM subjects. Linear regression analyses showed an independent association between asprosin and insulin resistance. According to the logistic regression analyses, the subjects with the highest asprosin levels increased the probability of nT2DM prevalence. Conclusions: Increased asprosin levels associated with insulin resistance and unfavorable outcomes of metabolic parameters in subjects with nT2DM

Keywords

Type 2 diabetes mellitus, asprosin, insulin resistance, metabolic syndrome

References

• Romere C, Duerrschmid C, Bournat J, et al. Asprosin, a Fasting- Induced Glucogenic Protein Hormone. Cell 2016;165:566–579. [CrossRef]
• Duerrschmid C, He Y, Wang C, et al. Asprosin is a centrally acting orexigenic hormone. Nat Med 2017;23:1444–1453. [CrossRef]
• Zhang L, Chen C, Zhou N, Fu Y, Cheng X. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clin Chim Acta 2019;489:183–188. [CrossRef]
• Acara, A.C., Bolatkale, M., Kızıloğlu, İ., İbişoğlu, E., Can, Ç.: A novel biochemical marker for predicting the severity of ACS with unstable angina pectoris: Asprosin. Am J Emerg Med 2018; 36:1504–1505. [CrossRef]
• Alan M, Gurlek B, Yilmaz A, et al. Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol 2018;35:220–223. [CrossRef]
• Lee T, Yun S, Jeong JH, Jung TW. Asprosin impairs insulin secretion in response to glucose and viability through TLR4/JNK-mediated inflammation. Mol Cell Endocrinol 2019;486:96–104. [CrossRef]
• Marshall BA, Ren JM, Johnson DW, et al. Germline manipulation of glucose homeostasis via alteration of glucose transporter levels in skeletal muscle. J Biol Chem 1993;268:18442–18445. Available at: [CrossRef]
• De Fronzo RA, Tripathy D. Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes. Diabetes Care 2009;32:S157– S163. [CrossRef]
• Kahn BB. Type 2 diabetes: when insulin secretion fails to compensate for insulin resistance. Cell 1998;92:593–596. [CrossRef]
• Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 2017;128:40–50. [CrossRef]
• Taylor R. Insulin Resistance and Type 2 Diabetes. Diabetes 2012;61:778–779. [CrossRef]
• 2. Classification and Diagnosis of Diabetes. Diabetes Care. 40, S11– S24 (2017).
• Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735–52. [CrossRef]
• Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C.: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28, 412–9 (1985).
• Wang Y, Qu H, Xiong X, et al. Plasma Asprosin Concentrations Are Increased in Individuals with Glucose Dysregulation and Correlated with Insulin Resistance and First-Phase Insulin Secretion. Mediators Inflamm 2018;9471583. [CrossRef]
• Wang C-Y, Lin T-A, Liu K-H, et al. Serum asprosin levels and bariatric surgery outcomes in obese adults. Int J Obes 2018;43:1019–1025. [CrossRef]
• Wu L, Parhofer KG. Diabetic dyslipidemia. Metabolism 2014;63:1469– 1479. [CrossRef]